Skip to main content

Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability



Several subunits of the SWI/SNF chromatin remodeling complex are implicated in both cancer and neurodevelopmental disorders (NDD). Though there is no clinical evidence for an increased tumor risk in individuals with NDDs due to germline mutations in most of these genes so far, this has been repeatedly proposed and discussed. A young woman with NDD due to a de novo mutation in ARID1B now presented with a large renal (> 19 cm in diameter) and multiple hepatic angiomyolipomas (AMLs) but no other signs of tuberous sclerosis complex.


We analyzed tumor and healthy tissue samples with exome and panel sequencing.


Additionally to the previously known, germline ARID1B variant we identified a post-zygotic truncating TSC2 variant in both renal and hepatic AMLs but not in any of the healthy tissues. We did not detect any further, obvious tumor driver events. The identification of a passenger variant in SIPA1L3 in both AMLs points to a common clonal origin. Metastasis of the renal AML into the liver is unlikely on the basis of discordant histopathological features. Our findings therefore point to very low-grade mosaicism for the TSC2 variant, possibly in a yet unknown mesenchymal precursor cell that expanded clonally during tumor development. A possible contribution of the germline ARID1B variant to the tumorigenesis remains unclear but cannot be excluded given the absence of any other evident tumor drivers in the AMLs.


This unique case highlights the blurred line between tumor genetics and post-zygotic events that can complicate exact molecular diagnoses in patients with rare manifestations. It also demonstrates the relevance of multiple disorders in a single individual, the challenges of detecting low-grade mosaicisms, and the importance of proper diagnosis for treatment and surveillance.

Peer Review reports


ARID1B haploinsufficiency (OMIM #135900, *614556) represents a frequent cause for neurodevelopmental disorders (NDD) [1] comprising nonspecific intellectual disability [2] or Coffin-Siris syndrome [3, 4]. The AT-rich interactive domain-containing protein 1B encoded by the ARID1B gene is a subunit of the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling complex. This complex and many of its components play an important role in a broad spectrum of neoplasms, acting mainly as tumor suppressors [5]. ARID1B therefore belongs to a growing number of genes in which germline mutations cause NDDs while somatic mutations are involved in cancer [6]. Though there is no clinical evidence that individuals with NDDs due to germline mutations in most of these genes and particularly in ARID1B bear an increased risk for tumors [6, 7], this has been repeatedly proposed and discussed [3, 8].

We report on a young woman previously diagnosed with intellectual disability due to a de novo mutation in ARID1B, in whom a huge renal and multiple hepatic angiomyolipomas (AMLs) were diagnosed. Investigating their molecular cause revealed a post-zygotic stop-variant in TSC2 in addition to the previously known germline variant in ARID1B.


Clinical report

This individual had been reported previously (patient 5) when the de novo variant c.3304C > T, p.(Arg1102*) in ARID1B (NM_020732.3) was identified to be causative for her intellectual disability [2]. Clinical details up to 12 years 8 months are described elsewhere [2]. At age 19 she had moderate cognitive impairment with good comprehension, speaking in two-word sentences and friendly behavior. After indicating abdominal pain, examination by ultrasound and computer tomography (CT) revealed a large (diameter 19 cm) tumor in the left kidney and multiple liver tumors (> 8, average diameter ca. 2 cm) (Fig. 1a-c). Histological investigation after nephrectomy and removal of one of the liver tumors confirmed them to be AMLs (Fig. 1d-f). Subsequent cranial MRI (magnetic resonance imaging), ultrasound of the right kidney and detailed skin and nail examination did not reveal any further clinical features of tuberous sclerosis complex such as subependymal nodules or cortical dysplasia, skin lesions or ungual fibromas. Apart from two single seizures in early infancy she had no history of epilepsy. Meanwhile, cardiologic evaluation and computer tomography of the lung did not reveal further anomalies.

Fig. 1

Renal and hepatic AMLs. a Abdominal CT scan showing the large AML of the left kidney. b CT of the liver showing three lesions indicated by arrows. c Macroscopic picture of the renal AML. d Histopathology with haematoxylin and eosin (HE) staining showing blood vessels lacking elastic tissue (“angio”), smooth muscle cells (“myo”) and adipose tissue (“lipoma”) close together as a typical sign of angiomyolipoma. e HE staining of a region from the large kidney AML showing the ordinary smooth muscle differentiation and rhabdoid/epithelioid cell features. f HE staining of a region from the resected hepatic AML, being composed mainly of fat cells

DNA extraction and sequencing

DNA from peripheral blood lymphocytes (PBL) was extracted by standard procedures. DNA from cultured fibroblasts (obtained from a cleft palate surgery specimen) and from renal tubular cells grown from a urine specimen of the remaining healthy kidney as described by others [9] were extracted using the Qiagen DNAeasy system according to manufacturer’s recommendations (Qiagen, Hilden, Germany).

Genomic DNA from marked tumor and neighboring non-neoplastic tissues was extracted from 5 μm sections. After de-paraffinization the NucleoSpin Tissue kit was used according to the manufacturer’s protocol (Macherey-Nagel, Düren, Germany), and subsequently lysis with proteinase K at a concentration of 0.8–1.0 U per digest at 55 °C overnight was performed. Exome sequencing of DNA from blood, renal and liver tumor was performed on an Illumina HiSeq 2500 system (Illumina, Inc., San Diego, USA) after enrichment with the SureSelect Target Enrichment v6 technology (Agilent Technologies, Santa Clara, CA). Sequencing of DNA from unaffected renal and hepatic tissues and from fibroblasts and renal tubular cells was performed on an Illumina MiSeq system using the TruSight Cancer panel. Complete coverage (>20x) for TSC1 (NM_000368.3) and TSC2 (NM_000548.3) was ensured. MLPA analysis for TSC1 and TSC2 on PBL DNA was performed using the kits P046 and P124 from MRC-Holland (Amsterdam, The Netherlands). Variants in TSC2 and SIPA1L3 (NM_015073.2) were validated by Sanger sequencing using standard procedures.

Resulting sequencing reads were aligned and processed as described previously [10]. Concurrent variant calling of the two AML and the PBL exome BAM files together with 13 control samples from the same machine run was performed using freebayes version 1.1.0 [11]. SnpEff/SnpSift version 4.3p [12] with dbNSFP [13] was used for annotation. Potential somatic variants at coding and splice region positions from the freebayes calls were filtered to have an alternative allele fraction (AF) ≤1% in blood and of ≥5% in the respective tumor. Only sites with a read coverage of ≥10 in each sample and with ≥5 alternative allele reads in the tumor were considered. Additionally, variants present with an allele depth of ≥2x in 13 in-house controls from the same run were excluded. Copy number variation (CNV) screening from exome data was done with CNVkit version 0.9.4.dev0 [14]. BAM files were then visually inspected at regions of interest using the IGV browser version 2.4.7 [15, 16].


Analysing exome data from blood and renal and hepatic AMLs showed the known variant in ARID1B, as expected, in about 50% of the reads, respectively (Fig. 2a and Additional file 1: Figure S1). No further pathogenic variant in ARID1B, nor loss of heterozygosity (LOH) was observed in tumor tissues (Additional file 1: Figures S2 and S3). Analysis of TSC1 and TSC2 revealed the pathogenic variant c.3099C > G, p.(Tyr1033*) [17] in TSC2 (NM_000548.4) in 67.3% (270/401) of the reads in DNA from the renal and in 41.2% (49/119) of reads from the hepatic AML, while it was not detected in any of the 179 reads from blood (Fig. 2a and Additional file 1: Figure S1). Panel sequencing on DNA from unaffected renal and liver tissues and from fibroblasts did not detect the TSC2 variant in any of the 31 to 508 reads, respectively (Fig. 2a and Additional file 1: Figure S4), but in one of 1210 reads in DNA from tubular cells. However, given its location at the beginning of the read and as it occurred in only one read in an overlapping read pair, it most likely represents an artefact (Fig. 2a and Additional file 1: Figure S5).

Fig. 2

Molecular analyses on various tissues. a Overview of the analyzed tissue samples using exome, panel or Sanger sequencing and the results for the respective genomic regions of interest. Both somatic variants in TSC2 and SIPA1LR were identified and confirmed. No evidence for complete LOH at the ARID1B and TSC2 loci was found in the AML samples. Also see Additional file 1: Figures S1, S4 and S5 for details including IGV snapshots and Sangers sequencing results. b Schematic 2 × 2 contingency table of the different possible hypotheses for the tumor formation with arguments supporting each of the four combinations; the color intensity encodes perceived likeliness. VAF, variant allele frequency; CR, copy ratio; *: this one read is likely an artefact, compare Additional file 1: Figure S5

Searching exome data for additional variants in renal or hepatic AML and absent in blood revealed a variant in SIPA1L3 (c.187_192dup, p.(Ala63_Thr64dup) (NM_015073.2); COSM5959440), which was additionally excluded by Sanger sequencing in DNA from fibroblasts and healthy renal and hepatic tissues. Dysfunction of SIPA1L3 has been discussed as a possible contributor to the phenotype of some malignancies as it led to abnormalities of epithelial cell morphogenesis, cytoskeletal structure and adhesion in a colorectal adenocarcinoma cell line and as somatic SIPA1L3 alterations were found in various, mainly epithelial cancer types [18, 19]. However, it has not yet been reported as a tumor driver ( [20] and Cosmic Cancer Gene Census (CGC)), and it was not found to be mutated in a study searching for additional somatic mutations in TSC-related lesions [21]. Therefore, we consider this variant most likely a passenger variant, though we cannot exclude a contributing effect in the tumor pathogenesis in our patient. Copy number analysis from exome data indicated a possible deletion of TSC2 in a subpopulation of tumor cells. However, analysis of heterozygous variant positions at this locus did not show a significant deviation from 0.5, therefore not supporting validity of this finding (Additional file 1: Figures S2 and S3 and Additional file 2). These analyses are challenged by variability in exome data (e.g. coverage uniformity) and compromised tumor purity. No other large regions of LOH or CNVs were detected in the kidney or liver AMLs, indicating a relatively stable constellation in both tumors (Additional file 1: Figures S2 and S3; Additional file 2).


Tuberous Sclerosis Complex (TSC; OMIM #191100, *605284, #613254, *191092) is a multisystemic disorder generally caused by germline variants in TSC1 or TSC2. Multiple renal and extra-renal angiomyolipomas (AMLs) represent one of the characteristic manifestations of TSC. Renal AMLs are commonly observed in 80% of patients, while hepatic AMLs are less frequent and occur in ca. 13% of affected individuals [22]. When renal and hepatic AMLs were detected in the herewith reported individual with ARID1B associated NDD and without other frequent and typical signs of TSC, we considered various possibilities: a) The AMLs might be causally related to the germline ARID1B mutation. b) The AMLs represent a mild and atypical manifestation of TSC in the sentence of multiple diagnoses as reported recently in a large study that revealed aberrations in two or more disease loci in 4.9% of 7374 individuals with various phenotypes tested by clinical exome sequencing [23]. Or c) Another cause, un-related to the known ARID1B variant and not necessarily deducible from the AML phenotype might be responsible for the unusual presentation.

When performing exome sequencing on DNA from the renal and hepatic AMLs, we found no indication for a contribution of ARID1B or other commonly cancer-related genes such as TP53 to their genesis. While exome sequencing on blood did not detect a variant in the TSC genes TSC1 or TSC2, we detected the same pathogenic TSC2 variant in both renal and hepatic tumor tissues. This and an additional variant in SIPA1L3 also exclusively found in both AMLs underline their common clonal origin and open two possibilities: a) the multiple hepatic AMLs being metastases from the huge renal AML as rarely reported particularly for epithelioid AMLs [24], or b) the AMLs resulting from a low-grade mosaicism for the TSC2 variant. The first possibility seems extremely unlikely based on the discordant histopathological features of the AMLs. The huge renal tumor was predominantly composed of epithelioid cells entrapping only a very minor fatty component. In contrast, the resected hepatic AML was almost devoid of such epithelioid cells and was composed almost exclusively of fat cells closely mimicking a lipoma. Further supporting the second possibility, mosaicism has been frequently observed for TSC2 variants, including low-grade mosaicism with allele frequencies < 1% or variants only detected in skin tumor biopsies but not in blood or saliva [25].

Of note, we did not reliably observe the TSC2 variant in any of the sequencing reads from unaffected kidney, unaffected liver, fibroblasts or renal tubular cells, which might be expected in case of mosaicism. Given that the lesional cell of these TSC-related mixed neoplasms, the so-called “perivascular epithelioid cell” (PEC) has no known physiological counterpart, renal and hepatic AMLs might have their origin in a common, yet unknown mesenchymal precursor cell that expanded clonally during tumor development [26]. This has previously been discussed for the co-occurrence of sporadic pulmonary lymphangioleiomatosis and renal AMLs with somatic TSC2 variants [27] and for TSC-associated AMLs [28]. Presence of the TSC2 variant in only very few tumor precursor cells might therefore hinder detection in healthy tissues even by next-generation-sequencing (overview in Fig. 2b).

In contrast to many other tumors, AMLs are genetically relatively stable, and bi-allelic loss of TSC2 has been postulated as a sufficient and the main driver for AML development [28]. Given the absence of a second TSC2 variant, TSC2-LOH or any other evident tumor driver apart from the unclear variant in SIPA1L3 in the renal and hepatic AMLs of the herewith reported individual, a contribution of the germline ARID1B variant to the tumorigenesis cannot be excluded.

In any case, identifying the TSC2 variant in the herewith reported individual has important consequences for her medical care. It now prompts TSC specific surveillance including regular echocardiograms, high-resolution computed tomography of the lung and brain MRIs in addition to regularly checks of the remaining kidney and the liver. As mTOR inhibitors have been proven to be an efficient therapy in TSC [29], this treatment option will be evaluated and discussed based on her future disease course and manifestations.

Despite a good sequencing depth of 179 reads the TSC2 variant was not detectable in blood, meaning that it also would not have been detected as an incidental finding when performing exome sequencing because of the NDD and thus would not have resulted in predictive counseling and surveillance procedures. Proper medical care in individuals with mental handicap is often challenging due to limited expression of medical discomfort and thus missed co-morbidities or health complications unrelated to the initial diagnosis.


Next to the value of combining genetic and pathologic findings, this unique case demonstrates and emphasizes several generally important aspects of genetic and medical care such as a) considering multiple (independent) diagnoses in a single individual, b) considering mosaicism or post-zygotic variants and taking the efforts to detect them, as c) a proper diagnosis might have important consequences on treatment and surveillance. These efforts can be challenged by potential mosaicism in multi-tumor syndromes where the mutation-carrying cell of origin is still unknown and might represent a very minor yet unidentifiable cell population leading to false-negative results.





Copy number variant


Loss of heterozygosity


Magnetic resonance imaging


Neurodevelopmental disorder


Peripheral blood lymphocytes


Perivascular epithelioid cell


SWItch/Sucrose Non-Fermentable


Tuberous sclerosis complex


  1. 1.

    Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542(7642):433–8.

    Article  Google Scholar 

  2. 2.

    Hoyer J, Ekici AB, Endele S, Popp B, Zweier C, Wiesener A, Wohlleber E, Dufke A, Rossier E, Petsch C, et al. Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet. 2012;90(3):565–72.

    CAS  Article  Google Scholar 

  3. 3.

    Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, et al. Mutations affecting components of the SWI/SNF complex cause coffin-Siris syndrome. Nat Genet. 2012;44(4):376–8.

    CAS  Article  Google Scholar 

  4. 4.

    Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilhorst-Hofstee Y, et al. Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause coffin-Siris syndrome. Nat Genet. 2012;44(4):379–80.

    CAS  Article  Google Scholar 

  5. 5.

    Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11(7):481–92.

    CAS  Article  Google Scholar 

  6. 6.

    Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci. 2014;17(6):764–72.

    CAS  Article  Google Scholar 

  7. 7.

    Santen GW, Aten E, Vulto-van Silfhout AT, Pottinger C, van Bon BW, van Minderhout IJ, Snowdowne R, van der Lans CA, Boogaard M, Linssen MM, et al. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat. 2013;34(11):1519–28.

    CAS  Article  Google Scholar 

  8. 8.

    Agaimy A, Foulkes WD. Hereditary SWI/SNF complex deficiency syndromes. Semin Diagn Pathol. 2018.

  9. 9.

    Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, et al. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012;7(12):2080–9.

    CAS  Article  Google Scholar 

  10. 10.

    Hauer NN, Popp B, Schoeller E, Schuhmann S, Heath KE, Hisado-Oliva A, Klinger P, Kraus C, Trautmann U, Zenker M, et al. Clinical relevance of systematic phenotyping and exome sequencing in patients with short stature. Genet Med. 2018;20(6):630–38.

  11. 11.

    Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv: 12073907. 2012.

  12. 12.

    Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, Ruden DM, Lu X. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front Genet. 2012;3:35.

    Article  Google Scholar 

  13. 13.

    Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013;34(9):E2393–402.

    CAS  Article  Google Scholar 

  14. 14.

    Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.

    Article  Google Scholar 

  15. 15.

    Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.

    CAS  Article  Google Scholar 

  16. 16.

    Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178–92.

    CAS  Article  Google Scholar 

  17. 17.

    Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80.

    CAS  Article  Google Scholar 

  18. 18.

    Greenlees R, Mihelec M, Yousoof S, Speidel D, Wu SK, Rinkwitz S, Prokudin I, Perveen R, Cheng A, Ma A, et al. Mutations in SIPA1L3 cause eye defects through disruption of cell polarity and cytoskeleton organization. Hum Mol Genet. 2015;24(20):5789–804.

    CAS  Article  Google Scholar 

  19. 19.

    Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

    Article  Google Scholar 

  20. 20.

    Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650.

    Article  Google Scholar 

  21. 21.

    Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, Sisson KA, Koeman J, Weisenberger DJ, Cottingham SL, et al. The genomic landscape of tuberous sclerosis complex. Nat Commun. 2017;8:15816.

    CAS  Article  Google Scholar 

  22. 22.

    Fricke BL, Donnelly LF, Casper KA, Bissler JJ. Frequency and imaging appearance of hepatic angiomyolipomas in pediatric and adult patients with tuberous sclerosis. AJR Am J Roentgenol. 2004;182(4):1027–30.

    Article  Google Scholar 

  23. 23.

    Posey JE, Harel T, Liu P, Rosenfeld JA, James RA, Coban Akdemir ZH, Walkiewicz M, Bi W, Xiao R, Ding Y, et al. Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med. 2017;376(1):21–31.

    CAS  Article  Google Scholar 

  24. 24.

    He W, Cheville JC, Sadow PM, Gopalan A, Fine SW, Al-Ahmadie HA, Chen YB, Oliva E, Russo P, Reuter VE, et al. Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors. Mod Pathol. 2013;26(10):1355–64.

    Article  Google Scholar 

  25. 25.

    Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, et al. Mosaic and Intronic mutations in TSC1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing. PLoS Genet. 2015;11(11):e1005637.

    Article  Google Scholar 

  26. 26.

    Bonetti F, Pea M, Martignoni G, Doglioni C, Zamboni G, Capelli P, Rimondi P, Andrion A. Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma--the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology. 1994;26(3):230–6.

    CAS  Article  Google Scholar 

  27. 27.

    Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97(11):6085–90.

    CAS  Article  Google Scholar 

  28. 28.

    Giannikou K, Malinowska IA, Pugh TJ, Yan R, Tseng YY, Oh C, Kim J, Tyburczy ME, Chekaluk Y, Liu Y, et al. Whole exome sequencing identifies TSC1/TSC2 Biallelic loss as the primary and sufficient driver event for renal Angiomyolipoma development. PLoS Genet. 2016;12(8):e1006242.

    Article  Google Scholar 

  29. 29.

    Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071–81.

    CAS  Article  Google Scholar 

Download references


The authors would like to thank the family for participating and supporting this study. We thank Leonora Klassen, Antje Serwotka, Heike Friebel and Natascha Leicht for excellent technical assistance.


C.Z. was supported by grants from the German Research Foundation (DFG, ZW184/1–2, ZW184/3–1 and GRK2162) and by the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (E26), A.R. was supported by the German Ministry of Education and Research (BMBF, grant numbers: 01GS08160, 01GM1520A (Chromatin-Net)) and the IZKF Erlangen (E16). We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding programme Open Access Publishing.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to individual privacy regulations but are available from the corresponding author on reasonable request.

Author information




BP and CZ conceived the study. AA prepared and analyzed the histological sections. MW and CZ provided patients’ data and performed clinical assessments. KXK and MW provided the renal tubular cells. BP, SU, AE, CK and AR, and CZ analyzed and interpreted the molecular data. BP and CZ wrote and edited the manuscript with input from all co-authors. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Christiane Zweier.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethical review board of the Friedrich-Alexander-University Erlangen-Nürnberg (Ref. No. 253_15B). Informed written consent from the patient’s legal guardian was obtained.

Consent for publication

Written consent for publication of clinical details was obtained from the patient’s legal guardian.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional files

Additional file 1:

Figure S1. IGV snapshots from exome sequencing. Figure S2. Copy number analysis from exome data from the kidney AML using CNVkit. Figure S3. Copy number analysis from exome data from the liver AML using CNVkit. Figure S4. IGV snapshots from targeted Cancer Panel and Sanger sequencing. Figure S5. IGV snapshot of the artefact read identified in tubulus cells. (DOCX 1912 kb)

Additional file 2:

Exome CNV calls and heterozygous SNPs in the ARID1B or TSC2 region. Microsoft Excel spreadsheet file containing the worksheets “summary”, “CNVkit_exome-aberrations” and “LOH_ARID1BandTSC2”. The “summary” worksheet contains a detailed description of all other worksheets and the respective data columns. The “CNVkit_exome-aberrations” worksheet contains all the segments called by CNVkit 0.9.4.dev0 which have a copy numer different from 2. The “LOH_ARID1BandTSC2” worksheet contains all heterozygous single nucleotide variants called in the PBL and both kindey and liver AML samples with at least 20 bp coverage in each sample (to reduce sampling bias) with 500 k bases of the ARID1B (chr6[hg19]:156599064–158,031,913) or TSC2 (chr16[hg19]:1597990–2,638,713) gene. Fisher’s exact test from R version 3.4.3 was used to calculate p-values between the PBL and AML read coverages at each SNV position to check for significant deviation from the expected allele fraction. (XLSX 48 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Popp, B., Agaimy, A., Kraus, C. et al. Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability. BMC Cancer 19, 435 (2019).

Download citation


  • ARID1B
  • TSC2
  • Tuberous sclerosis complex
  • Neurodevelopmental disorders
  • Angiomyolipoma
  • Mosaic